1. HIV-1 polymorphisms
======================

In the 24 years since the discovery of HIV-1 [@B1], with the impetus to cure AIDS, there have been an unprecedented number of publications examining retroviral polymorphisms. These have led to significant advances in understanding mechanisms generating them. In particular, when a provirus replicates along with host cellular DNA during mitosis, progeny are extremely homogenous. A case in point is clonal expansion of HTLV-1 [@B2], resulting in small variability over centuries [@B2]-[@B5]. This can be attributed to the high fidelity of mammalian cellular DNA replication, mediated by the 3\'-5\' exonuclease proofreading activity of DNA polymerase [@B6].

When a provirus replicates exogenously by infection, progeny can be extremely heterogeneous [@B4], [@B7]. Since exogenous retroviral replication involves transcription and reverse transcription, both could contribute towards generating polymorphisms. However, RNA polymerase appears to have transcript-assisted proofreading activity [@B8]. Therefore, for exogenously replicating retroviruses, such as HIV-1, polymorphisms are primarily generated during error prone reverse transcription (Fig. [1](#F1){ref-type="fig"}) [@B9], [@B10].

In particular the mis-incorporations produced by RNA-templated DNA synthesis and DNA-templated DNA synthesis (Fig. [1](#F1){ref-type="fig"}), have been proven to be exacerbated by dNTP imbalances both in vitro and in vivo [@B11]-[@B14]. Proof of the existence of these dNTP imbalances in a proportion of retroviral permissive cells [@B13] has provided a mechanistic explanation for observed retroviral G to A hypermutations in vivo [@B11], [@B13]-[@B17]. These mis-incorporations result in polymorphisms, since reverse transcriptase lacks 3\'-to-5\' exonuclease proof-reading activity [@B18], provided that the mutations result in replication competent virus that is naturally selected in vivo. More recently, RNA editing, through APOBEC enzymes, that deaminate cytosine to uracil, have also been proposed as a mechanism for retroviral G to A hypermutation [@B19]. In fact, the newest role for the HIV-1 Vif protein, is to counter the effect of APOBEC [@B20], [@B21]. Interestingly, Vif may also be exploiting the mutation potential afforded by APOBEC, in generating more HIV-1 diversity [@B21], rather than simply providing immunity from the innate host APOBEC defense mechanism.

Importantly, both templated and non-templated miss-incorporations, as well as "slippage", can occur during the jumps of reverse transcription (Fig. [1](#F1){ref-type="fig"}) [@B22]. Therefore, in addition to point mutations, in vivo sampled retroviruses also frequently harbor deletions and insertions. Here, among the most probable mechanistic explanations, in addition to, or in combination with the above mentioned non-templated additions, is forced copy-choice strand switching during reverse transcription followed by mis-alignment and continued polymerization on the new template [@B23]-[@B28]. In essence this is a forced emulation of the reverse transcription \"jumps\" depicted in figure [1](#F1){ref-type="fig"} [@B29]. This mechanism reconciles the fact that retroviruses can synthesize cDNA with only one RNA genomic copy [@B30] whereas viral particles carry 2 copies. The second would then serve the failsafe function of providing new template to \"jump to\" when reverse transcriptase encounters a nick. In addition, forced copy choice strand-switching provides a probable mechanistic explanation for phylogenetic revelations of inter-subtype recombinant HIV isolates [@B15], [@B31]. The implication is that chimeric exogenous retroviruses, containing transcribed genomic RNA from two different proviruses, are produced from doubly or multiply infected cells. In fact, recombination has now been shown to be the primary driving force for generating HIV-1 variants [@B32], [@B33], despite cellular retroviral superinfection resistance mechanisms [@B34].

The above retroviral mutation mechanisms highlight how retroviruses can generate sequence diversity. These mechanisms are shared by the larger family of elements capable of retro-transposition [@B7], [@B35]. However, HIV-1 undergoes such rapid exogenous viral replication and turnover [@B36]-[@B38], that natural selection generates enormously heterogeneous populations termed quasispecies [@B16], [@B39], or swarms, which have either temporally adapted to cell-specific microenvironments, or exist because their specific polymorphisms are neutral.

2. The MFNLP
============

The proviral HIV-1 LTR sequences first investigated, were from the initial isolate [@B40] and rapidly became the prototypical LTR. These sequences orchestrate the cellular RNA polymerase II transcription machinery, in conjunction with viral proteins, and include a TATA-box, 3 SP1 sites, 2 NFkB enhancer elements, an RBEIII site and an upstream USF site (Fig. [2](#F2){ref-type="fig"}A) (reviewed in [@B41]). Importantly, the extensive HIV-1 polymorphism detected in vivo, extends to the LTR ([@B15], [@B42] and references therein).

In particular, a length polymorphism immediately 5\' of the enhancer region, has been detected, investigated, or referred to by a growing list of publications [@B42]-[@B60]. This polymorphism was initially detected as a 24 base pair duplication by Golub, Li and Volsky, looking for LTR variants; but no regulatory cis-acting motifs were described within it, despite a correlation with increased transcription [@B43]. Blumberg and co-authors, described a similar duplication, in adult and pediatric patients, while looking for variant nef sequences, but again did not find any motifs that might explain functional significance [@B44]. Koken and co-authors, were the first to refer to this duplication as the "CTG"-motif, and noted that it encompassed a repeat of the sequence 5\'-ACTGCTGA-3\', and further found that a single "CTG"-motif virus, could out-compete an isogenic virus containing the duplication, in co-culture experiments, in 42 days [@B45]. These authors also noted similarities between the duplicated region and the recently-described TCF-1α (hLEF) binding site, and pointed out that HIVANT 70, as well as SIVCPZ, have the duplicated "CTG"-motif ([@B45] and references therein). These authors also pointed out that Nakanishi, Masamune and Kobayashi, had described the "CTG"-motif region as a novel cis-acting, cell-specific element [@B61]. In fact, in their paper, Nakanishi and co-authors designated this region (-157 to -121) the Upstream Regulatory Element (URE) and showed that it bound a transcription factor (designated URE-binding factors C1 and C2, by EMSA-specific analysis with nuclear extracts) distinct from AP-1 [@B61]. Furthermore, Koken and co-authors [@B45] noted that Zeichner, Kim and Alwine, had published data suggesting positive regulation in the "CTG"-motif region [@B62]. Soon afterwards, Kim, Gonzales, Zeichner and Alwine, published another paper, showing a more profound effect of mutations in the URE-region ("CTG"-motif), in the context of chromatin and viral replication, but attributed the effect to mutation of the TCF-1α (hLEF) binding-site [@B63]. In another paper by Koken and co-authors, they extended their initial finding, first showing that "CTG"-motif deleted, and "CTG"-motif duplicated isogenic viruses, are out-competed in cell culture assays by the monomeric isomeric virus [@B46]. These authors also showed that a Circa 64kD protein, binds with specificity to the 5\'-ACTGCTGA-3\' sequence, duplicated in the "CTG"-motif duplications and obtained similar EMSA results to those of Nakanishi and co-authors, but further reported no correlation between the "CTG"-motif duplication and disease stage or viral phenotype [@B46], [@B61]. So, by 1994, it was already clear that a cis-element, named URE, enhanced viral replication, contained a putative binding site for TCF-1α (hLEF), could specifically bind proteins from nuclear extracts, and was encompassed in a frequent Nef/LTR duplication ("CTG"-motif duplication). Furthermore it was clear that whatever the in vivo function of the "CTG"-motif duplication, in tissue culture assays with isogenic viruses, no dramatic effects were observed.

Further reports on this region of the HIV-1 LTR, included a paper from Michael and co-authors, that detected the TCF-1α duplication in uncultured samples from patients, and suggested it may mediate a repressive effect [@B47], and a paper by Ait-Khaled, also detecting the TCF-1α duplication, in post-mortem samples [@B48]. However, in 1996, in a cross-sectional analysis of nearly 500 HIV-1 LTRs, we published that the "CTG"-motif or URE region duplications, could best be aligned as a single larger polymorphism, which we named the most frequent naturally-occurring length polymorphism (MFNLP) of the HIV-1 LTR [@B42]. Furthermore, we proposed that the MFNLP encompassed a binding site for an unpublished nuclear factor named RBF-2, instead of TCF-1α [@B42]. This transcription factor was defined in a subsequent publication [@B64], by a TGA-specificity for the 5\'-ACTGCTGA-3\' sequence, in crude nuclear extracts, and correlated with a region of the HIV-1 LTR required for optimal responsiveness to Ras signaling through the MAPK pathway, in tissue culture transient transfections. This sequence was named the Ras- responsive binding element III (RBEIII) [@B64]. Strikingly, a subsequent publication by Linqi Zhang and co-authors, reported a TCF-1α duplication in a patient that progressed towards AIDS, despite the lack of NFκB binding [@B49]. Interestingly, these authors suggested a compensatory role for the TCF-1α duplication, in the face of NFκB binding-site abrogation, yet they found very little effect of the duplication in tissue culture [@B49]. Soon after, Kirchhoff and co-authors, reported on the presence of the MFNLP sequence in clinical samples, but did not point out that they duplicated RBEIII sequences, responsive to Ras [@B50]. Similarly, Zhang and co-authors, reported on more clinical samples with TCF-1α duplications, for which they found no phenotype, but failed to point out that the MFNLPs duplicated RBEIII [@B51]. Quinones-Mateu, reported similar detection of sequence duplications, which we called MFNLPs [@B53]. In 1998, we further expanded our knowledge about the RBEIII and MFNLP-binding proteins, by showing: (i) that hLEF (TCF-1α) can footprint on the wild type site but not on all MFNLPs or RBEIII sites; (ii) that all MFNLPs bind RBF-2; and (iii) that a small repressive effect was mediated through the MFNLP in transient transfections [@B65]. In 1999 Naghavi and co-authors also reported TCF-1α duplications in clinical samples [@B55], [@B66]. At this time, we had already attempted to purify the components of RBF-2 by chromatography, including an oligo-affinity step [@B67]. Purified RBF-2 included proteins of approximately 120 kD and 45kD, however our repeated attempts to obtain peptide sequences from large scale purifications were inconclusive [@B67].

Importantly, in the lab of Robert Roeder, Naghavi and I began doing some experiments to confirm her sequencing data that predicted various HIV-1 subtypes would not bind to the NRE USF site, since the sequence was not highly conserved, as I had shown for samples from the long-standing Vancouver Lymphadenopathy Study (VLAS) cohort [@B42]. While studying the role of USF-1 in HIV-1 LTR-directed transcription and viral replication, we used a double stranded RBEIII site and a mutant RBEIII site, as a non-specific competitor in an EMSA with labeled double stranded E-box targets, encompassing the upstream USF-1 site in the prototypical LAV HIV-1 LTR sequence, and nuclear extracts (NRE B USF site, Fig [2](#F2){ref-type="fig"}B, lane1). Surprisingly, we found that at 100X molar excess, RBEIII competed with the band shift, but the RBEIII mutant did not (Fig [2](#F2){ref-type="fig"}B, lane 9 versus lane 10). Although we at first assumed we had made a mistake, we immediately tested our new hypothesis that RBF2 contains USF-1, by competing a standard nuclear extract RBF2-RBEIII EMSA, with the E-box unlabelled target (Fig. [2](#F2){ref-type="fig"}C, lane 2). The hallmark of the RBF2 EMSA (Fig [2](#F2){ref-type="fig"}C, lane 1) is competition with 100X wild type RBEIII (Fig. [2](#F2){ref-type="fig"}C, lane 5) in the face of no competition with 100X mutant RBEIII (Fig. [2](#F2){ref-type="fig"}C, lane 4). The specific RBF2 bands were further tested with the non-specific 100X wtNFκB sequences from the prototype LAV HIV-1 LTR (Fig. [2](#F2){ref-type="fig"}C, lane 3). This important result indicated that our initial observation was true, and suggested that RBF2 contains USF-1. We therefore compared the EMSA mobility of rUSF-1 versus nuclear extracts, with an RBEIII target (Fig. [2](#F2){ref-type="fig"}D). The standard RBF-2 EMSA (Fig. [2](#F2){ref-type="fig"}D, lanes 1-4, lower arrow) appears to have a specific band that is lower in mobility than the specific band forming with rUSF-1 (Fig. [2](#F2){ref-type="fig"}D, lanes 5-10). Importantly, although the mobility is slightly different, both bands are specific, since the nuclear extract band can be competed with 100X molar excess of wtRBEIII (lane 2) but not with 100X mut RBEIII (lane 3) and the rUSF-1 band can be competed with 100X wtRBEIII (lane 8) but not 100X mutRBEIII (lane 9). Additionally, antibodies to rUSF-1 appear to supershift both RBF-2 and rUSF-1 (lanes 4 and 10), consistent with USF-1 being in RBF-2. Since our focus is on the MFNLP and MFNLPs encompass RBEIII sequences, the above results strongly suggested that MFNLPs would also bind USF-1. However, the canonical E-box CANNTG site, recognized by USF-1, is not present in RBEIII sites. Indeed Target Detection Analysis (TDA), with random targets, using USF-1, does not select an RBEIII site [@B68]. However, we noted that in the purified RBF-2 preparations there was a circa 120 kD component [@B67]. It was then Robert Roeder who immediately suggested to me that RBF-2 was comprised of USF and TFII-I. Because TFIIi and USF-1 bind the initiator/E-box region of the HIV-1 LTR, and RBF-2 had been shown to bind an RBEI site (in addition to the RBEIII site) that overlaps with the initiator sequences (Fig.[2](#F2){ref-type="fig"}A) [@B64], the hypothesis that RBF-2 was comprised of USF and TFII-I seemed plausible. In fact, I found this was indeed the case, for at least 2 naturally occurring RBEIII HIV-1 LTR sequences (from clones pMCE36.1 and pMCE9.104, described elsewhere [@B65]), one of which is encompassed in an MFNLP (pMCE9.104) (Fig. [2](#F2){ref-type="fig"}D), in addition to the prototype HIV-1 LTR LAV sequences (above). Importantly, since binding of rUSF-1 alone (Fig. [2](#F2){ref-type="fig"}D, lanes 1 and 2) and binding of rTFIIi alone (lanes 5 and 6) is significantly weaker than when USF-1 is combined with TFIIi (lanes 3 and 4), it is likely that cooperative binding was occurring. Indeed, this important result suggested that USF-1 and TFIIi, when integrated at an RBEIII site, exert a stronger effect than individually, thus potentially explaining why their individual binding to an RBEIII site has not been previously observed.

Subsequent to our discovery, we asked the laboratory of Ivan Sadowski to confirm our results. Martin Hirst detected both USF and TFII-I in RBF-2 purifications [@B67], confirming our results. All the above initial findings were excluded from our publication about the NRE USF subtype sites [@B69], in order to better develop them into a clearer picture of the function of USF/TFII-I at the RBEIII sites, in collaboration with the lab of Ivan Sadowski (see below) [@B70].

Importantly, Jeeninga and co-authors, confirmed in 2000, that RBEIII sites are absolutely conserved, in LTR subtypes A through G [@B66]. A publication in 2000 by Gomez-Roman and co-authors, detected MFNLP sequences, duplicating RBEIII, in a long term non progressor (LTNP), but no deletions to RBEIII sites were found [@B56]. These LTNP are clinically distinct groups with lower viral replication and a slower or non-progressive form of HIV-1 infection (see below).

In 2000, Chen and co-authors found that an MFNLP from one of their patient samples, created a new AP-1 binding site, and identified c-Fos and JunB as binding proteins for their MFNLP [@B57]. Birch and co-authors described in 2001, LTNP from the Sydney Blood Bank Cohort (SBBC), that are accumulating progressively more LTR/Nef deletions, and some of these persons harbor RBEIII duplications in the form of MFNLPs [@B58]. Similarly, another LTNP study appears to have LTR/Nef sequences progressively accumulating greater deletions over time [@B60]. However it has not been at all clear if the LTR or the Nef deletions are responsible for the LTNP phenotype.

In 2002, Hiebenthal-Millow and Kirchhoff, found that in primary T cells, the MFNLP appears not to confer a major effect upon viral replication in culture [@B59]. A noteworthy observation about this paper is that these authors actually found enhanced transcriptional activity occurred when both the RBEIII site and MFNLPs were deleted, and that the MFNLP slightly reduced transcriptional activity.

Perhaps the most important paper about the role of the RBEIII site and the MFNLP is that from Chen and co-authors [@B70]. This paper expands on our initial discovery that RBF-2 is composed of TFIIi and USF, based on the TGA specificity of the EMSA used by Bell and Sadowski [@B64]. RBF-2 appears to be a heterodimer of USF-1/USF-2; and TFII-I appears to load USF-1/ USF-2 onto the RBEIII site. Importantly, this paper shows that RBEIII mutant LTRs are unresponsive to cross-linking of the T cell receptor or stimulation with PMA and ionomycin. Thus it appears that the phenotype of the RBEIII site and hence the compensatory MFNLP role, is to provide a target for Ras/MAPK activation of the HIV-1 LTR, in the context of chromatin [@B70], [@B71].

3. Nef, LTNP and RBF-2
======================

Importantly, the most recent SBBC LTNP study, indicates that there is a convergence in LTR/Nef deletions for these LTNPs [@B72]. These deletions appear to leave the sequences downstream of the NFκB sites intact, yet appear to be abrogating RBEIII sites, since they are deleted, without MFNLPs. Importantly, there are publications indicating that Nef can activate the MAPK pathway [@B73] and increase T cell activation [@B74]. Therefore Nef could be actually acting through the Nef/LTR cis-acting RBEIII site, which is abrogated in the SSBC LTNPs [@B72]. I therefore propose the model in figure [3](#F3){ref-type="fig"}. LTRs with normal RBEIII sites and a normal Nef sequence, could contribute to high viral replication and progress to AIDS (Fig [3](#F3){ref-type="fig"}A). The presence of MFNLPs in the context of normal RBEIII sites would simply provide a failsafe function. However, LTRs with mutated RBEIII site would require an MFNLP, as a compensatory mechanism (Fig [3](#F3){ref-type="fig"} B). If however, LTRs receive difficult-to-revert Nef deletions, either after an RBEIII mutation (Fig. [3](#F3){ref-type="fig"}C) or prior to an RBEIII mutation (Fig. [3](#F3){ref-type="fig"}D), then the selective pressure to maintain the RBEIII site and the MFNLP disappears. The result of this model, would explain the convergent deletions observed in the LTR/Nef SSBC LTNP study, as well as being consistent with the role for RBF-2, RBEIII and MFNLPs.

Whether my model about LTNP is true or not, the conserved nature of the RBEIII sites in vivo, makes it an important potential target for delivery of chimeric transcription factor repressors, which could emulate the LTNP phenotype, by blocking activation through this highly conserved site [@B75]. This is illustrated in Figure [4](#F4){ref-type="fig"}, where a chimeric transcription factor encompassing a repressor (such as MCEF[@B75], [@B76]) and a DNA binding partner (RBF-2), might have the potential to both block tat-transactivation and interfere with the function of RBEIII.

I thank Mojgan Naghavi for providing her data (Fig. [2](#F2){ref-type="fig"}D), Robert Roeder for use of his lab and reagents between 1998 and 2001, Ivan Sadowski for the use of his lab and reagents between 1993 and 1998, and Martin Hirst for his role in confirming our RBF-2 preparations in the Sadowski lab contained USF and TFII-I. Maksymillian Niedzielski helped with making the figures and Robert Hopewell helped with the bibliography. The writing of this review was supported in part by grants from Canfar, CFI, OIT, NSERC and CIHR.

Figures and Tables
==================

![**The MFNLP is generated during reverse transcription. (A)** Synthesis of minus strong stop DNA, begins with t-RNA (clover-leaf structure) binding to the primer binding site (pbs), followed by RNA-templated polymerization of minus strong stop DNA (dashed arrow). RNase H degrades the template RNA after polymerization (arrows); **(B)**Template switching to the other RNA genome copy or to the same RNA, occurs via complementary sequences in the Repeat region (R). During the template switch, slippage can occur; **(C)** Minus strand extension could combine with slippage, templated and non-templated polymerization, resulting in duplication of the URE/RBEIII/partial E-box region (single white box, in RNA U3 region), generating a first copy of the MFNLP (two white boxes in U3 region), in the minus DNA. RNAse H continues to degrade the RNA genome, leaving just the polypurine tracts. **(D)** Initial synthesis of plus strand DNA begins from the central polypurine tract (cppt) and from the 3\'-polypurine tract (3\'-ppt), resulting in synthesis of a plus strand MFNLP (four white boxes); **(E)** Annealing of the free pbs, further extension and rearrangements, are followed by nuclear import and integration of the proviral HIV-1 sequences. **(F)** The final integrated proviral sequences contain a 5\'-LTR and a 3\'-LTR with U3, R, U5 sequences. In this model, both the 5\' and 3\'-LTR would contain the MFNLP. Note the Nef ORF in the 3\'-LTR and the Nef/LTR sequences in the 5\'-LTR. Integrity of the Nef TGA stop codon (ACTGC[TGA]{.ul}) is critical for RBF-2 binding to the MFNLP.](ijbsv03p0318g01){#F1}

![**MFNLPs and RBEIII, bind USF-1 and TFIIi. (A)**Schematic representation of the HIV-1 LTR. Some transcription factors landmarks (NFAT, USF-1, RBF2, NFkB, SP-1) known to interact with target sequences on the HIV-1 LTR are indicated in their relative positions. The -121 position where the MFNLPs occur is indicated, with the MFNLP above, bound by RBF2 at the MFNLP RBEIII site. The -453 and +185 sites indicate the extremes of the LTR. The +1 site indicates the start of transcription and the +98 site, the end of Tar sequences. The dashed circles represent the approximate positions of two nucleosomes (Nuc-0 and Nuc-1). **(B) RBEIII sequences specifically compete with a USF EMSA.** The dsNREB oligosed as targets for the respective Hela nuclear extracts. Inclusion of competitor DNA sequences is indicated by a plus sign. **(C) A USF-1 site competes specifically with RBF2 for an RBEIII site.** A p32-labelled wt RBEIII ds oligo was used as target in EMSA with nuclear extracts from HeLa-s cells (NE, lanes 1-5). The target site that the respective competitor ds oligo sequences encompass, are designated with a + sign above each lane, and are listed on the right top of the panel. **(D) rUSF-1 specifically binds to RBEIII, but results in a higher mobility EMSA than RBF2.**A p32-labelled wt RBEIII ds oligo was used as target in EMSA with nuclear extracts from HeLa-s cells (NE, lanes 1-4) or with rUSF-1 (lanes 5-10). The target site that the respective competitor ds oligo sequences encompass, are designated with a + sign above each lane, and are listed on the right top of the panel. Lower arrow: NE-RBEIII (RBF2) complex. Upper arrow: rUSF-1-RBEIII complex. (D) rTFIIi and rUSF-1 bind cooperatively to MFNLP and wt RBEIII sites from 2 patients. A p32-labelled ds oligonucleotide target, encompassing the RBEIII site of either clone pMCE36.1 (lanes 1, 3, 5) or pMCE9.104 (lanes 2, 4, 6) was used as target in EMSA with either rUSF-1, TFIIi, or both, as indicated with a + sign above each lane, and listed at the right top of the panel. Lower arrow: Free pMCE36.1 ds oligonucleotide. Upper arrow: Free pMCE9.104 ds oligonucleotide. (B to E) The NRE, RBEIII, USF, NFκB sequences and EMSA conditions have been previously described [@B55], [@B64], [@B65], [@B67], [@B69].](ijbsv03p0318g02){#F2}

![**MFNLPs compensate for RBEIII mutations, by maintaining functional coupling, of Nef and RBF-2.**In this schematic representation four states are considered. In A & B, normal progressive disease with high viral titer would develop. In C & D, difficult-to-revert-mutations to Nef or the RBEIII site, would result in LTNP, and deletions of both RBEIII LTR sequences and Nef sequences. This is because, in our model, Nef can activate the MAPK pathway, and exert its effects through RBEIII.](ijbsv03p0318g03){#F3}

![**Chimeric Transcription Factor Repression (CTFR) of HIV-1.**Delivery of a repressor with the ability to interfere with Tat-transactivation and bind to the RBEIII/ MFNLP is hypothesized. The HIV-1 LTR is drawn with some salient transcription factors indicated. The RNA stem-loop structure termed TAR, can form a ternary complex with HIV-1 TA and P-TEFb, to hyperphosphorylate the carboxy terminal domain (CTD) of RNA Polymerase II (PolII). Because MCEF interacts with P-TEFb and represses HIV-1 Tat-transactivation, if tethered to the RBEIII/ MFNLP site, MCEF could interfere with the binding of RBF-2 (3) and tat transactivation (1 and 2).](ijbsv03p0318g04){#F4}
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